TNFRSF18 and hepatocellular carcinoma: Future research should focus on expanding the concurrent infiltration of GITR with various immune biomarkers, suggesting the promising effect of GITR as a part of combination immunotherapeutic options, an area that is already a part of several clinical trials on HCC patients.